Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412M Deal

News Snapshot:

BlackJack3D Deals and Financings Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine (IRON) of Watertown, MA in a deal worth up to $412 million. Mabwell will receive $10 million upfront (see story). 9MW3011 is designed to lower the serum level of iron, regulating iron homeostasis in vivo. It is expected to treat patients with rare diseases including β-thalassemia, polycythemia vera and other conditions related to iron homeostasis. 9MW3011, which has been approved to start trials in China and the US, was developed in Mabwell's San Diego Innovation R&D Center. Zhuhai's Biotheus formed a multi-year collaboration...